These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2494734)

  • 1. Comparative microscopic study on response of Ehrlich carcinoma to BNCT vs. chemo- and radiotherapy.
    Samarrai SF; al-Mufti AW; Hikmat S; Karim JM; al-Hayani R; Sugano H; Saito T; Tsukagoshi S; Amano K; Hatanaka H
    Strahlenther Onkol; 1989; 165(2-3):217-8. PubMed ID: 2494734
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced survival in a rat glioma model following BNCT.
    Clendenon NR; Barth RF; Goodman JH; Staubus AE; Gordon WA; Moeschberger ML; Alam F; Soloway AH; Fairchild RG; Slatkin DN
    Strahlenther Onkol; 1989; 165(2-3):222-5. PubMed ID: 2494736
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives of the clinical BNCT of malignant gliomas in Czechoslovakia.
    Sourek K; Tovarys F
    Strahlenther Onkol; 1989; 165(2-3):247-9. PubMed ID: 2494741
    [No Abstract]   [Full Text] [Related]  

  • 4. Canine spontaneous brain tumors--a large animal model for BNCT.
    Gavin PR; Kraft SL; Wendling LR; Miller DL
    Strahlenther Onkol; 1989; 165(2-3):225-8. PubMed ID: 2494737
    [No Abstract]   [Full Text] [Related]  

  • 5. Biological efficacy of thermal neutrons using Na2(10)B12H11SH studied in vivo on B-16 mouse melanoma.
    Spryshkova R; Naidenov M; Borisov G; Komkov M; Bratsev V; Serebryakov N; Demidov A
    Strahlenther Onkol; 1989; 165(2-3):213-5. PubMed ID: 2494732
    [No Abstract]   [Full Text] [Related]  

  • 6. Boron determination for neutron capture therapy by colorimetry and emission spectrometry.
    Strouf O; Mertenová E; Schneiderová L; Zámecníková H; Janků I
    Strahlenther Onkol; 1989; 165(2-3):174-6. PubMed ID: 2494723
    [No Abstract]   [Full Text] [Related]  

  • 7. Biological efficacy of a boronated porphyrin as measured in cell culture.
    Laster BH; Kahl SB; Kalef-Ezra J; Popenoe EA; Fairchild RG
    Strahlenther Onkol; 1989; 165(2-3):203-5. PubMed ID: 2494728
    [No Abstract]   [Full Text] [Related]  

  • 8. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
    Maruyama K; Ishida O; Kasaoka S; Takizawa T; Utoguchi N; Shinohara A; Chiba M; Kobayashi H; Eriguchi M; Yanagie H
    J Control Release; 2004 Aug; 98(2):195-207. PubMed ID: 15262412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.
    Obayashi S; Kato I; Ono K; Masunaga S; Suzuki M; Nagata K; Sakurai Y; Yura Y
    Oral Oncol; 2004 May; 40(5):474-82. PubMed ID: 15006618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boronophenylalanine for neutron capture therapy of melanoma.
    Coderre JA; Glass JD; Fairchild RG; Micca P; Kalef-Ezra J
    Strahlenther Onkol; 1989; 165(2-3):215-7. PubMed ID: 2494733
    [No Abstract]   [Full Text] [Related]  

  • 11. Fast neutrons for BNCT.
    Wagner FM; Koester L
    Strahlenther Onkol; 1989; 165(2-3):115-7. PubMed ID: 2494712
    [No Abstract]   [Full Text] [Related]  

  • 12. Applicability of the 2-nitroimidazole-sodium borocaptate-10B conjugate, TX-2060, as a 10B-carrier in boron neutron capture therapy.
    Masunaga S; Nagasawa H; Hiraoka M; Sakurai Y; Uto Y; Hori H; Nagata K; Suzuki M; Maruhashi A; Kinashi Y; Ono K
    Anticancer Res; 2004; 24(5A):2975-83. PubMed ID: 15517904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The relative biologic effectiveness (RBE) of fast neutrons as measured by the intensity of tumor cell fluorescence in the ultraviolet region of the spectrum].
    Merkle K
    Vopr Onkol; 1975; 21(12):69. PubMed ID: 1210130
    [No Abstract]   [Full Text] [Related]  

  • 14. Plan for synthesis of biomolecules for neutron capture therapy of cervical carcinoma.
    Wongwiechintana C; Choonchartprasert S; Tampitak S; Prachayasittigul S
    Strahlenther Onkol; 1989; 165(2-3):125-6. PubMed ID: 2494715
    [No Abstract]   [Full Text] [Related]  

  • 15. The United States BNCT program.
    Robertson JS; Mahoney FJ
    Strahlenther Onkol; 1989; 165(2-3):249-51. PubMed ID: 2494742
    [No Abstract]   [Full Text] [Related]  

  • 16. Boronated monoclonal antibodies for potential neutron capture therapy of malignant melanoma and leukaemia.
    Tamat SR; Patwardhan A; Moore DE; Kabral A; Bradstock K; Hersey P; Allen BJ
    Strahlenther Onkol; 1989; 165(2-3):145-7. PubMed ID: 2494717
    [No Abstract]   [Full Text] [Related]  

  • 17. Boron chemistry and target cell affinity.
    Soloway AH; Alam F; Barth RF; Bapat BV
    Strahlenther Onkol; 1989; 165(2-3):118-20. PubMed ID: 2494713
    [No Abstract]   [Full Text] [Related]  

  • 18. Conjugation, purification and characterization of boronated monoclonal antibodies for use in neutron capture therapy.
    Barth RF; Mafune N; Alam F; Adams DM; Soloway AH; Makroglou GE; Oredipe OA; Blue TE; Steplewski Z
    Strahlenther Onkol; 1989; 165(2-3):142-5. PubMed ID: 2494716
    [No Abstract]   [Full Text] [Related]  

  • 19. Integrated approach in the planning of neutron capture therapy.
    Ryabukhin YS
    Strahlenther Onkol; 1989; 165(2-3):158-62. PubMed ID: 2494721
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiation field for BNCT experiments.
    Csom G; Zsolnay EM; Fehér S; Virágh E
    Strahlenther Onkol; 1989; 165(2-3):78-81. PubMed ID: 2494749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.